CoChat

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial

Open access

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Abstract

Background & aims Ursodeoxycholic acid (UDCA) is used for treatment of primary biliary cirrhosis. Previous studies showed that, compared with UDCA monotherapy, bile salts plus prednisolone had no further effect on laboratory data but improved liver histology. Thirty percent of these patients had prednisolone-related side effects. Budesonide is a glucocorticoid with a high receptor affinity and a high first-pass metabolism. In this study we investigated whether budesonide and UDCA are superior to UDCA monotherapy.Methods A 2-year prospective, controlled double-blind trial was performed. Twenty patients (mainly with early-stage disease) were treated with UDCA at a dose of 10-15 mg/kg daily in addition to 3 mg budesonide 3 times daily (group A), and 19 patients (1 dropped out for personal reasons) were treated with UDCA plus placebo (group B). Liver biopsy specimens were taken before, after 12 months, and at the end of study. Glucose tolerance tests, serum cortisol levels, and adrenocorticotropin-stimulated cortisol secretion were assessed at regular intervals. Bone mass density was measured by dual-energy photon absorptiometry.Results Compared with pretreatment values, liver enzyme and immunoglobulin M and G levels decreased significantly in both groups. Improvement in group A was significantly more pronounced (P < 0.05) than in group B. Titers of antimitochondrial antibodies did not change. In group A, the point score of liver histology improved by 30.3%; in group B, it deteriorated by 3.5% (P < 0.001). Changes in bone mineral density after 2 years were -1.747% in group A and -0.983% in group B (P = 0.43). Budesonide had little influence on the hypothalamic-pituitary-adrenal axis. One patient in group A had budesonide-related side effects; in 3 patients in group B, complications of liver disease developed.Conclusions Combination therapy with UDCA and budesonide is superior to UDCA and placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0016-5085(99)70351-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 2

  1. David, 1985, Die Wirkung von Ursodesoxycholsäure bei chronischen Leberkrankheiten. Eine Pilotstudie (abstr), Z Gastroenterol, 23, 420
  2. Wür thwein, 1992, Lipophilicity and receptor affinity of glucocorticoids, Pharm Ztg Wiss, 137, 161

Cited by

See all 252

Metadata

Authors
Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U.
Affiliations
  • University Hospital Frankfurt (DE)
  • Klinikum Esslingen (DE)
  • Goethe University Frankfurt (DE)
Venue
Gastroenterology
Publisher
Elsevier BV
Published
1999-10
Volume
117
Issue
4
Pages
918-925
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2075487592
Cited by
247
References
33
Citations by year
2026: 1 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 7 · 2018: 14 · 2017: 9 · 2016: 12 · 2015: 19 · 2014: 16 · 2013: 9 · 2012: 9
FWCI
5.09
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
primary biliary cirrhosis, budesonide, ursodeoxycholic acid, combination therapy, glucocorticoids, bile salts, liver histopathology, bone mineral density, hypothalamic-pituitary-adrenal axis, antimitochondrial antibodies
MeSH terms
Administration, Oral, Administration, Topical, Anti-Inflammatory Agents, Cholagogues and Choleretics, Double-Blind Method, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunoglobulin G, Immunoglobulin M, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Prospective Studies, Ursodeoxycholic Acid, Treatment Outcome, Budesonide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. https://app.cochat.ai/papers/10.1016/s0016-5085(99)70351-3
The paper
Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999). Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. Gastroenterology. https://doi.org/10.1016/s0016-5085(99)70351-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.